Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19.

Saved in:
Bibliographic Details
Title: Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19.
Authors: Miller PG; Center for Cancer Research and Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA.; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA., Fell GG; Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA., Foy BH; Department of Pathology & Center for Systems Biology, Massachusetts General Hospital, Boston, MA.; Department of Systems Biology, Harvard Medical School, Boston, MA., Scherer AK; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Gibson CJ; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA., Sperling AS; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA.; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Burugula BB; Department of Human Genetics, University of Michigan, Ann Arbor, MI., Nakao T; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA.; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.; Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.; Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Uddin MM; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA.; Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA., Warren H; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA., Bry L; Department of Pathology, Brigham and Women's Hospital, Boston, MA., Pozdnyakova O; Department of Pathology, Brigham and Women's Hospital, Boston, MA., Frigault MJ; Center for Cancer Research and Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA., Bick AG; Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Neuberg D; Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA., Higgins JM; Department of Pathology & Center for Systems Biology, Massachusetts General Hospital, Boston, MA.; Department of Systems Biology, Harvard Medical School, Boston, MA., Mansour MK; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Natarajan P; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA., Kim AS; Department of Pathology, Brigham and Women's Hospital, Boston, MA., Kitzman JO; Department of Human Genetics, University of Michigan, Ann Arbor, MI., Ebert BL; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA.; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.; Howard Hughes Medical Institute, Bethesda, MD.
Source: Blood [Blood] 2022 Nov 03; Vol. 140 (18), pp. 1993-1997.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0020
DOI:10.1182/blood.2022018052